Preferred Label : Keytruda;
Origin ID : M000597704;
UMLS CUI : C3855203;
Related record
- Semantic type(s)
https://www.has-sante.fr/jcms/p_3420797/fr/keytruda-pembrolizumab-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
breast neoplasms
pembrolizumab
breast cancer
pembrolizumab
Childhood Breast Carcinoma
Pembrolizumab
neoplasm, malignant
Male Breast Carcinoma
Keytruda
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3327389/fr/keytruda-pembrolizumab-cancer-de-l-œsophage
https://www.has-sante.fr/jcms/p_3327401/fr/decision-n-2022-0182/dp/sem-du-30-mars-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
Esophagus cancer
Esophagus
pembrolizumab
esophagospasm
cancer of esophagus
Keytruda
neoplasm, malignant
pembrolizumab
Esophagus
pembrolizumab
esophageal neoplasms
---
https://www.has-sante.fr/jcms/p_3325579/fr/keytruda-pembrolizumab-cancer-de-l-endometre
https://www.has-sante.fr/jcms/p_3325589/fr/decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
https://www.has-sante.fr/jcms/p_3329013/fr/decision-n-2022-0109/dc/sem-du-31-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
French
evaluation of the transparency committee
pembrolizumab
cancer
neoplasm, malignant
Endometrium cancer
Keytruda
endometrium
pembrolizumab
Endomet
endometrial neoplasms
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3325988/fr/keytruda-pembrolizumab-cancer-du-sein
https://www.has-sante.fr/jcms/p_3325999/fr/decision-n-2022-0084/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
breast cancer
breast neoplasms
Keytruda
pembrolizumab
pembrolizumab
pembrolizumab
Breast cancer
neoplasm, malignant
---
https://www.has-sante.fr/jcms/p_3296560/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2021
France
evaluation of the transparency committee
Keytruda
Breast cancer
pembrolizumab
triple negative breast neoplasms
pembrolizumab
breast cancer
neoplasm, malignant
pembrolizumab
triplets
---
https://www.has-sante.fr/jcms/p_3112911/fr/keytruda
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
pembrolizumab
pembrolizumab
Metastatic Lung Non-Small Cell Squamous Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
carcinoma, non-small-cell lung
adult
carcinoma, squamous cell
carboplatin
paclitaxel
Albumin-Bound Paclitaxel
infusions, intravenous
Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen
Carboplatin/Paclitaxel/Pembrolizumab Regimen
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3117084/fr/keytruda
2019
false
false
false
France
pembrolizumab
pembrolizumab
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-carcinome-urothelial
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-pembrolizumab-anticorps-monoclonal-carcinome-urothelial
2018
false
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
pembrolizumab
treatment outcome
survival analysis
Urothelial Carcinoma
urologic neoplasms
infusions, intravenous
pembrolizumab
antineoplastic agents
antineoplastic agents
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2825867/fr/keytruda-vessie-1ere-ligne
2018
false
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
urinary bladder neoplasms
Urothelial Neoplasm
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2885795/fr/keytruda
2018
false
false
false
France
Antineoplastic Agents, Immunological
pembrolizumab
melanoma
adult
carcinoma, non-small-cell lung
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2780761/fr/keytruda
2017
false
false
false
France
French
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2774645/fr/keytruda-cbnpc-1ere-ligne
https://www.has-sante.fr/portail/jcms/c_2774645/fr/keytruda-pembrolizumab-anticorps-anti-pd1-cbnpc-1ere-ligne
2017
false
false
false
France
French
evaluation of the transparency committee
pembrolizumab
guidelines for drug use
pembrolizumab
treatment outcome
infusions, intravenous
programmed cell death 1 receptor
programmed cell death 1 receptor
neoplasm metastasis
carcinoma, non-small-cell lung
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
